Par Drugs and Chemicals Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Par Drugs and Chemicals Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 33% of its market value (net cash). Higher than almost all Healthcare companies in India.
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 98% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 98% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹129Over the last 3 years, every ₹100 of reported profit came with ₹129 of operating cash.
Higher than 60% of Healthcare companies in India.
Self-Funding Ratio
5.7×Over the last 3 years its own operating cash covered its investment spending (capex) 5.7 times.
Higher than 93% of Healthcare companies in India.
Cash Locked Ratio
₹9For every ₹100 of sales, ₹9 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹14 tied up three years earlier.
Less money tied up than 74% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 1/3Sales grew in 3 of the last 3 years; profit grew in 1 of 3.
Less steady than 68% of Healthcare companies in India.
Growth Efficiency Ratio
₹23Sales grew 8% in 3 years; of every extra ₹100 of sales, ₹23 became extra profit.
Higher than 70% of Healthcare companies in India.
Asset Productivity Ratio
+8% / +45%In 3 years sales changed by +8% while total assets changed by +45%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
No debt dueNo debt falls due within a year, according to the latest yearly balance sheet.
Cash Cushion Ratio
+33%Cash, after subtracting all debt, equals 33% of its market value (net cash).
Higher than almost all Healthcare companies in India.
Tangible Assets Ratio
100%Of every ₹100 the company owns, ₹100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 98% of Healthcare companies in India.
Tangible Net Worth Ratio
100%Of every ₹100 of net worth, ₹100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 98% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Par Drugs and Chemicals Limited owes ₹0.13 for every ₹1 it owns. Net profit fell 2% in the year to Mar 2026, and grew 5% a year on average over 3 years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
9.8Investors pay ₹9.8 for every ₹1 of Par Drugs and Chemicals Limited's yearly profit, lower than 98% of Healthcare companies in India.
P/B ratio
1.15The share price is 1.15 times Par Drugs and Chemicals Limited's book value per share, lower than 97% of Healthcare companies in India.
Market cap
₹129 CrThe total market value of all of Par Drugs and Chemicals Limited's shares at today's price (share price × number of shares), smaller than 96% of Healthcare companies in India. PosiCap size class: Micro Cap.
Net worth (book value)
₹112 CrWhat Par Drugs and Chemicals Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹91.01Net worth divided by the number of shares. The share price of ₹104.60 is 1.1 times this, which is the P/B above.
Return on equity (ROE)
11.8%Par Drugs and Chemicals Limited earned 11.8% on its shareholders' money over the last year, lower than 57% of Healthcare companies in India.
Owes vs Owns
0.13×Par Drugs and Chemicals Limited owes ₹0.13 for every ₹1 it owns (low), lower than 94% of Healthcare companies in India.
Dividend yield
NonePar Drugs and Chemicals Limited does not currently pay a dividend.
Revenue growth
+2%Revenue rose 2% in the year to Mar 2026, and grew 3% a year on average over 3 years.
Profit growth
-2%Net profit fell 2% in the year to Mar 2026, and grew 5% a year on average over 3 years.
Profit margin
12.8%Par Drugs and Chemicals Limited keeps ₹13 of every ₹100 of revenue as net profit.
Cash quality
1.3×Cash from Par Drugs and Chemicals Limited's business was 1.3× its reported profit in the year to Mar 2026 — its profit turned into cash.
Cash vs debt
Net cashPar Drugs and Chemicals Limited held ₹42 Cr more cash than debt (net cash) at Mar 2026.
Questions
What is Par Drugs and Chemicals Limited's P/E ratio?
Investors pay ₹9.8 for every ₹1 of Par Drugs and Chemicals Limited's yearly profit, lower than 98% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Par Drugs and Chemicals Limited: ₹129 Cr ÷ ₹112 Cr (31 Mar 2026) = 1.1.
What is Par Drugs and Chemicals Limited's return on equity?
Par Drugs and Chemicals Limited earned 11.8% on its shareholders' money over the last year, lower than 57% of Healthcare companies in India.
How much does Par Drugs and Chemicals Limited owe compared with what it owns?
Par Drugs and Chemicals Limited owes ₹0.13 for every ₹1 it owns (low), lower than 94% of Healthcare companies in India.
Does Par Drugs and Chemicals Limited pay a dividend?
No. Par Drugs and Chemicals Limited does not currently pay a dividend.
Is Par Drugs and Chemicals Limited's revenue growing?
Revenue rose 2% in the year to Mar 2026, and grew 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.